Non-alcoholic fatty liver disease and hypertension: a bidirectional, mutually aggravating relationship
https://doi.org/10.31146/1682-8658-ecg-230-10-62-70
Abstract
This article presents a set of clinical guidelines for the management of patients with non-alcoholic fatty liver disease (NAFLD), a section on the specifics of managing patients with NAFLD and concomitant arterial hypertension (AH). The review examines the pathogenetic relationships of hypertension development in patients with NAFLD. The results of multicenter studies and meta-analyses demonstrating the relationship between these diseases are presented. The main directions of diagnostics and features of antihypertensive therapy in this category of patients are considered.
About the Authors
L. B. Lazebnik
Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
S. V. Turkina
Volgograd State Medical University
Russian Federation
Russian Federation
References
1. Ng C.H., Wong Z.Y., Chew N.W.S. et al. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med. 2022;9:942753. doi: 10.3389/fcvm.2022.942753.
2. Lorbeer R., Bayerl C., Auweter S. et.al. Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease. J Hypertens. 2017;35(4):737-744. doi: 10.1097/HJH.0000000000001245.
3. Fallo F., Dalla Pozza A., Sonino N. et al. Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. J Hypertens. 2008;26(11):2191-7. doi: 10.1097/HJH.0b013e32830dfe4b.
4. Latea L., Negrea S., Bolboaca S. Primary non-alcoholic fatty liver disease in hypertensive patients. AustralasMed J. 2013;6(6):325-30. doi: 10.4066/AMJ.2013.1648.
5. Vasunta R.L., Kesäniemi Y.A., Ylitalo A.S., Ukkola O.H. High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults. J Hypertens. 2012;30(10):2015-9. doi: 10.1097/HJH.0b013e3283576faf.
6. Ryoo J.H., Suh Y.J., Shin H.C. et al. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014;29(11):1926-31. doi: 10.1111/jgh.12643.
7. Sung K.C., Wild S.H., Byrne C.D. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol. 2014;60(5):1040-5. doi: 10.1016/j.jhep.2014.01.009.
8. Huh J.H., Ahn S.V., Koh S.B. et al. Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study. PLoS One. 2015;10(11): e0143560. doi: 10.1371/journal.pone.0143560.
9. Liu P., Tang Y., Guo X. et al. Bidirectional association between nonalcoholic fatty liver disease and hypertension from the Dongfeng-Tongji cohort study. J Am Soc Hypertens. 2018;12(9):660-670. doi: 10.1016/j.jash.2018.06.013.
10. Roh J.H., Park J.H., Lee H. et al. A Close Relationship between Non-Alcoholic Fatty Liver Disease Marker and New-Onset Hypertension in Healthy Korean Adults. Korean Circ J. 2020;50(8):695-705. doi: 10.4070/kcj.2019.0379.
11. Zhao Y.C., Zhao G.J., Chen Z. et al. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertension. 2020 Feb;75(2):275-284. doi: 10.1161/HYPERTENSIONAHA.119.13419.
12. Higashiura Y., Furuhashi M., Tanaka M. et al. Elevated Fatty Liver Index Is Independently Associated With New Onset of Hypertension During a 10-Year Period in Both Male and Female Subjects. J Am Heart Assoc. 2021;10(14): e021430. doi: 10.1161/JAHA.121.021430.
13. Ciardullo S., Grassi G., Mancia G., Perseghin G. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022;34(4):365-371. doi: 10.1097/MEG.0000000000002299.
14. Chongyang Ma, Kai Yan, Zisong Wang et al. The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis. Bioengineered. 2021;12:1:2187-2202. doi: 10.1080/21655979.2021.1933302.
15. Вonnet F., Gastaldelli A., Pihan-Le Bars F. et al.; D.E.S.I.R., RISC Study Groups. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. J Hypertens. 2017;35(3):493-500. doi: 10.1097/HJH.0000000000001204.
16. Song Q., Ling Q., Fan L. et al. Severity of non-alcoholic fatty liver disease is a risk factor for developing hypertension from prehypertension. Chin Med J (Engl). 2023;136(13):1591-1597. doi: 10.1097/CM9.0000000000002111.
17. Tsuneto A., Hida A., Sera N. et al. Fatty liver incidence and predictive variables. Hypertens Res. 2010;33(6):638-43. doi: 10.1038/hr.2010.45.
18. Aneni E.C., Oni E.T., Martin S.S. et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015;33(6):1207-14. doi: 10.1097/HJH.0000000000000532.
19. Wang Y., Zeng Y., Lin C., Chen Z. Hypertension and non-alcoholic fatty liver disease proven by transient elastography. Hepatol Res. 2016;46(13):1304-1310. doi: 10.1111/hepr.12688.
20. Huang Q., Yu H., Zhong X. et al. Association between hypertension and nonalcoholic fatty liver disease: a cross-sectional and meta-analysis study. J Hum Hypertens. 2023;37(4):313-320. doi: 10.1038/s41371-022-00686-w.
21. Yuan M., He J., Hu X. et al. Hypertension and NAFLD risk: Insights from the NHANES 2017-2018 and Mendelian randomization analyses. Chin Med J (Engl). 2024;137(4):457-464. doi: 10.1097/CM9.0000000000002753.
22. Gerui Li, Yuanyuan Peng, Ze Chen et al. Bidirectional Association between Hypertension and NAFLD: A Systematic Review and Meta-Analysis of Observational Studies.International Journal of Endocrinology. 2022; vol. 2022, Article ID 8463640, 10 pages. doi: 10.1155/2022/8463640.
23. Sorrentino P., Terracciano L., D’Angelo S. et al. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol. 2010;105(2):336-44. doi: 10.1038/ajg.2009.587.
24. Singh S., Allen A.M., Wang Z. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643-54.e1-9; quiz e39-40. doi: 10.1016/j.cgh.2014.04.014.
25. Labenz C., Huber Y., Kalliga E. et al. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment PharmacolTher. 2018;48(10):1109-1116. doi: 10.1111/apt.14976.
26. Gawrieh S., Wilson L.A., Cummings O.W. et al. NASH Clinical Research Network. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. Am J Gastroenterol. 2019;114(10):1626-1635. doi: 10.14309/ajg.0000000000000388.
27. Kanwal F., Kramer J.R., Li L., Dai J. et al. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020;71(3):808-819. doi: 10.1002/hep.31014.
28. Jaruvongvanich V., Wirunsawanya K., Sanguankeo A., Upala S. Nonalcoholic fatty liver disease is associated with coronary artery calcification: A systematic review and meta-analysis. Dig Liver Dis. 2016;48(12):1410-1417. doi: 10.1016/j.dld.2016.09.002.
29. Mahfood Haddad T., Hamdeh S., Kanmanthareddy A., Alla V.M. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes MetabSyndr. 2017;11 Suppl 1: S209-S216. doi: 10.1016/j.dsx.2016.12.033.
30. Zhou Y.Y., Zhou X.D., Wu S.J. et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatol Commun. 2018;2(4):376-392. doi: 10.1002/hep4.1155.
31. Wong M.Y.Z., Yap J.J.L., Sultana R. et al. Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis. Open Heart. 2021;8(2): e001850. doi: 10.1136/openhrt-2021-001850.
32. Duell P.B., Welty F.K., Miller M., et al; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6): e168-e185. doi: 10.1161/ATV.0000000000000153.
33. Hassen G., Singh A., Belete G. et al. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. Cureus. 2022;14(5): e25495. doi: 10.7759/cureus.25495.
34. Kjeldsen S.E. Hypertension and cardiovascular risk: General aspects. Pharmacol Res. 2018;129:95-99. doi: 10.1016/j.phrs.2017.11.003.
35. Dolgalev I.V., Ivanova A. Yu., Shipkhineeva A. Yu. Hypertension as a death risk factor in men and women aged 20-59 years: a 34-year cohort prospective study. Cardiovascular Therapy and Prevention. 2023;22(8):3602. (In Russ.) doi: 10.15829/1728-8800-2023-3602.@@ Долгалев И.В., Иванова А.Ю., Шипхинеева А.Ю. Артериальная гипертензия как фактор риска смерти у мужчин и женщин в возрасте 20-59 лет: 34-летнее когортное проспективное исследование. Кардиоваскулярная терапия и профилактика. 2023;22(8):3602. doi: 10.15829/1728-8800-2023-3602.
36. Martín-Fernández J., Alonso-Safont T., Polentinos-Castro E. et al. Impact of hypertension diagnosis on morbidity and mortality: a retrospective cohort study in primary care. BMC Prim Care. 2023 Mar 23;24(1):79. doi: 10.1186/s12875-023-02036-2.
37. Kuneinen S.M., Kautiainen H., Ekblad M.O., Korhonen P.E. Multifactorial prevention program for cardiovascular disease in primary care: hypertension status and effect on mortality. J Hum Hypertens. 2024;38(4):322-328. doi: 10.1038/s41371-024-00900-x.
38. Lonardo A., Nascimbeni F., Mantovani A., Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J. Hepatol. 2018;68:335-352. doi: 10.1016/j.jhep.2017.09.021.
39. Song Q.R., Liu S.L., Ling Q.H. et al. Severity of Nonalcoholic Fatty Liver Disease is Associated With Cardiovascular Outcomes in Patients With Prehypertension or Hypertension: A Community-Based Cohort Study. Front Endocrinol (Lausanne). 2022; 13:942647. doi: 10.3389/fendo.2022.942647.
40. Cattazzo F., Lombardi R., Mantovani A. et al. Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension. Nutr Metab Cardiovasc Dis. 2022;32(12):2839-2847. doi: 10.1016/j.numecd.2022.08.005.
41. Bataller R., Sancho-Bru P., Ginès P. et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003;125:117-125. doi: 10.1016/s0016-5085(03)00695-4.
42. Warner F.J., Lubel J.S., McCaughan G.W., Angus P.W. Liver fibrosis: a balance of ACEs? Clin Sci (Lond). 2007; 113:109-118. doi: 10.1042/CS20070026.
43. Sigala B., McKee C., Soeda J. et al. Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells. PLoS One. 2013;8: e72928. doi: 10.1371/journal.pone.0072928.
44. Lee H.J., Lee C.H., Kim S. et al. Association between vascular inflammation and non-alcoholic fatty liver disease: analysis by 18F-fluorodeoxyglucose positron emission tomography. Metabolism. 2017;67:72-79. doi: 10.1016/j.metabol.2016.11.004.
45. Mattson D.L. Immune mechanisms of salt-sensitive hypertension and renal end-organ damage. Nat Rev Nephrol. 2019;15:290-300. doi: 10.1038/s41581-019-0121-z.
46. [Chronic kidney disease (CKD)]. Clinical guidelines Ministry of Health of the Russian Federation 2024. ID: 469. (in Russ.) Available at: https://cr.minzdrav.gov.ru/recomend/469_3 (Accessed: 05.09.2024.)@@ Хроническая болезнь почек (ХБП). Клинические рекомендации Министерства здравоохранения РФ. ID: 469, 2024. https://cr.minzdrav.gov.ru/recomend/469_3
47. Goalstone M.L., Natarajan R., Standley P.R. et al. Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells. Endocrinology. 1998 Oct;139(10):4067-72. doi: 10.1210/endo.139.10.6270
48. Macvanin M., Gluvic Z., Radovanovic J. et al. New insights on the cardiovascular effects of IGF-1. Front Endocrinol (Lausanne). 2023 Feb 9;14:1142644. doi: 10.3389/fendo.2023.1142644.
49. Zhang Y., Zhang X.J., Wang P.X. et al. Reprogramming innate immune signaling in cardiometabolic disease. Hypertension. 2017;69:747-760. doi: 10.1161/HYPERTENSIONAHA.116.0819.
50. Brandes R.P. Endothelial dysfunction and hypertension. Hypertension. 2014;64:924-928. doi: 10.1161/HYPERTENSIONAHA.114.03575.
51. Cai J., Xu M., Zhang X., Li H. Innate immune signaling in nonalcoholic fatty liver disease and cardiovascular diseases. Annu Rev Pathol. 2019;14:153-184. doi: 10.1146/annurev-pathmechdis-012418-013003.
52. Cai J., Zhang X.J., Li H. Role of innate immune signaling in non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2018;29:712-722. doi: 10.1016/j.tem.2018.08.003.
53. Swiderska M., Maciejczyk M., Zalewska A. et al. A. Oxidative stress biomarkers in the serum and plasma of patients with non-alcoholic fatty liver disease (NAFLD). Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients. Free Radic Res. 2019:1-10. doi: 10.1080/10715762.2019.1635691.
54. Guzik T.J., Touyz R.M. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension. 2017;70:660-667. doi: 10.1161/HYPERTENSIONAHA.117.0780.
55. Adolph T.E., Grande C., Grabherr F., Tilg H. Adipokines and non-alcoholic fatty liver disease: multiple interactions.Int J Mol Sci. 2017;18: e1649. doi: 10.3390/ijms18081649.
56. Roja E., Rodríguez-Molina D., Bolli P. et al. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep. 2014;16:463. doi: 10.1007/s11906-014-0463-7.
57. Faulkner J.L., Belin de Chantemèle E.J. Sex differences in mechanisms of hypertension associated with obesity. Hypertension. 2018;71:15-21. doi: 10.1161/HYPERTENSIONAHA.117.09980.
58. Cao Z., Cheng Y., Li S. et al. Mediation of the effect of serum uric acid on the risk of developing hypertension: a population-based cohort study. J Transl Med. 2019;17(1):202. doi: 10.1186/s12967-019-1953-9.
59. Feig D.I. The role of uric acid in the pathogenesis of hypertension in the young. J Clin Hypertens (Greenwich). 2012;14(6):346-52. doi: 10.1111/j.1751-7176.2012.00662.x.
60. Jaruvongvanich V., Ahuja W., Wirunsawanya K., Wijarnpreecha K., Ungprasert P. Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(9):1031-1035. doi: 10.1097/MEG.0000000000000931.
61. Sun Q., Zhang T., Manji L. et al. Association Between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis. Clin Epidemiol. 2023;15:683-693. doi: 10.2147/CLEP.S403314.
62. Abbasi S., Haleem N., Jadoon S., Farooq A. Association Of Non-Alcoholic Fatty Liver Disease With Serum Uric Acid. J Ayub Med Coll Abbottabad. 2019;31(1):64-66. PMID: 30868786.
63. Cardiovascular prevention: correction of arterial hypertension, elevated lipid levels, NAFLD as cardiovascular risk factors. Diagnostic and treatment algorithms. Therapy. 2023; 9(4S): 52-86. (In Russ.) doi: 10.18565/therapy.2023.4suppl.52-86.@@ Сердечно-сосудистая профилактика: коррекция артериальной гипертензии, повышенного уровня липидов, НАЖБП как факторов кардиоваскулярного риска. Алгоритмы диагностики и лечения. Терапия. 2023; 9(4S): 52-86. doi: 10.18565/therapy.2023.4suppl.52-86.
64. Visseren F.L.J., Mach F., Smulders Y.M. et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-37. doi: 10.1093/eurheartj/ehab484.
65. Clinical guidelines. Non-alcoholic fatty liver disease in adults. All-Russian public organization “Russian Scientific Medical Society of Therapists”, Scientific Society of Gastroenterologists of Russia.Rubricator of clinical guidelines of the Ministry of Health of Russia. 2022. ID: 748. (In Russ.) Available at: https://cr.minzdrav.gov.ru/schema/748_1 (accessed: 05.09.2024.)@@ Клинические рекомендации. Неалкогольная жировая болезнь печени у взрослых. Общероссийская общественная организация «Российское научное медицинское общество терапевтов», Научное общество гастроэнтерологов России. Рубрикатор клинических рекомендаций Минздрава России. 2022. ID: 748. Доступ: https://cr.minzdrav.gov.ru/schema/748_1
66. Ivashkin V.T., Maevskaya M.V., Zharkova M.S. et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104-140. (In Russ.) doi: 10.22416/1382-4376-2022-32-4-104-140.@@ Ивашкин В.Т., Маевская М.В., Жаркова М.С. с соавт. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022; 32(4): 104-140. doi: 10.22416/1382-4376-2022-32-4-104-140.
67. Guan L., Miao P. The effects of taurine supplementation on obesity, blood pressure and lipid profile: A meta-analysis of randomized controlled trials. Eur J Pharmacol. 2020.885. P. 173533. doi: 10.1016/j.ejphar.2020.17353.
68. Sun Q., Wang B., Li Y. et al. Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension: Randomized, Double-Blind, Placebo-Controlled Study. Hypertension. 2016;67(3):541-9. doi: 10.1161/HYPERTENSIONAHA.115.06624.
69. Tzang C.C., Lin W.C., Lin L.H. et al. Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis. Nutr J. 2024 Aug 15;23(1):93. doi: 10.1186/s12937-024-00995-5.
70. Tzang C.C., Chi L.Y., Lin L.H., Lin T.Y., Chang K.V., Wu W.T., Özçakar L. Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Nutr Diabetes. 2024 May 16;14(1):29. doi: 10.1038/s41387-024-00289-z.
71. Clinical guidelines. Non-alcoholic fatty liver disease.Rubricator of clinical guidelines of the Ministry of Health of Russia. 2024. ID: 748. (In Russ.) Available at: https://cr.minzdrav.gov.ru/schema/748_1 (Accessed: 05.09.2024.)@@ Клинические рекомендации. Неалкогольная жировая болезнь печени. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 748. Доступ: https://cr.minzdrav.gov.ru/schema/748_1
72. Li Y., Xu H., Wu W. et al. Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Oncotarget. 2018;9(35):24155-24167. doi: 10.18632/oncotarget.23816.
73. Santos R.A., Ferreira A.J., Simoes E.S.A.C. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008; 93:519-27. doi: 10.1113/expphysiol.2008.042002.
74. Santos S.H., Fernandes L.R., Pereira C.S. et al. Increased circulating angiotensin-(1-7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet. RegulPept. 2012;178:64-70. doi: 10.1016/j.regpep.2012.06.009.
75. Bilman V., Mares-Guia L., Nadu A.P. et al. Decreased hepatic gluconeogenesis in transgenic rats with increased circulating angiotensin-(1-7) Peptides. 2012;37:247-51. doi: 10.1016/j.peptides.2012.08.002.
76. Silva A.R., Aguilar E.C., Alvarez-Leite J.I. et al. Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice. Am J Physiol Regul Integr Comp Physiol. 2013;305: R1323-1330. doi: 10.1152/ajpregu.00249.2013.
77. Moreira de Macedo S., Guimaraes T.A., Feltenberger J.D., Sousa Santos S.H. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides. 2014; 62:189-96. doi: 10.1016/j.peptides.2014.10.005.
78. Elhence H., Dodge J.L., Lee B.P. Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis. Clin Gastroenterol Hepatol. 2024 Feb;22(2):315-323.e17. doi: 10.1016/j.cgh.2023.07.009.
79. Goh G.B., Pagadala M.R., Dasarathy J. et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int. 2015 Mar;35(3):979-85. doi: 10.1111/liv.12611.
80. Mamedov M.N., Drapkina O.M. Choice of antihypertensive therapy in patients with arterial hypertension and chronic liver diseases. Rational Pharmacotherapyin Cardiology. 2008;4(4):65-68. (In Russ.) doi: 10.20996/ 1819-6446-2008-4-4-65-68.@@ Мамедов М.Н., Драпкина О.М. Выбор антигипертензивной терапии у больных с артериальной гипертонией и хроническими заболеваниями печени. Рациональная Фармакотерапия в Кардиологии. 2008;4(4):65-68. doi: 10.20996/1819-6446-2008-4-4-65-68.
81. Lazebnik L.B., Komissarenko I.A., Levchenko S.V. et al. SV Effect of angiotensin-converting enzyme inhibitors on renal and hepatic function in patients with arterial hypertension of older age groups. Liki Ukrainy. 2012;(1): 36-42. (In Russ.)@@ Лазебник Л.Б., Комиссаренко И.А., Левченко С.В. и др. Влияние ингибиторов ангиотензинпревращающего фермента на функцию почек и печени у больных артериальной гипертензией старших возрастных групп. Ліки України. 2012;(1): 36-42.
82. Paschos P., Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol. 2012;4:327-31. doi: 10.4254/wjh.v4.i12.327.
83. Вaran B., Akyuz F. Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? World J Gastroenterol. 2014;20:14219-29. doi: 10.3748/wjg.v20.i39.14219.
84. Yokohama S., Tokusashi Y., Nakamura K. et al.Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol. 2006;12:322-6. doi: 10.3748/wjg.v12.i2.322.
85. Yokohama S., Yoneda M., Haneda M. et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222-5. doi: 10.1002/hep.20420.
86. Meng C., Song Z., Zhang L. et al. Effects of losartan in patients with NAFLD: A meta-analysis of randomized controlled trial. Open Life Sci. 2023;18(1):20220583. doi: 10.1515/biol-2022-0583.
87. Hirata Т., Tomita K., Kawai T. et al. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY).Int J Endocrinol. 2013; 587140. doi: 10.1155/2013/587140.
88. Hirata Т., Tomita K., Kawai T. et al. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY).Int J Endocrinol. 2013; 587140. doi: 10.1155/2013/587140.
89. Borém L.M.A., Neto J.F.R., Brandi I.V. et al. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertens Res. 2018 Jun;41(6):394-405. doi: 10.1038/s41440-018-0040-6.
90. Park H.W., Lee J.H. Calcium channel blockers as potential therapeutics for obesity-associated autophagy defects and fatty liver pathologies. Autophagy. 2014;10(12):2385-6. doi: 10.4161/15548627.2014.984268.
91. Li Y., Zhao D., Qian M. et al. Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. Br J Pharmacol. 2022 May;179(9):2054-2077. doi: 10.1111/bph.15768.
92. Drapkina O.M., Korneeva O.N. Diroton in the treatment of arterial hypertension in patients with metabolic syndrome and non-alcoholic fatty liver disease (the CONDUCTOR study).Russian Medical News. 2013:18(3):41-9. (In Russ.)@@ Драпкина О.М., Корнеева О.Н. Диротон в лечении артериальной гипертензии у пациентов с метаболическим синдромом и неалкогольной жировой болезнью печени (исследование «ДИРИЖЕР»). Российские Медицинские Вести. 2013:18(3):41-9.
93. Liu Y., Boettcher M.F., Schmidt A. et al. Pharmacokinetics and safety of nifedipine GITS/candesartan fixed-dose combination in subjects with hepatic impairment.Int J Clin Pharmacol Ther. 2017 Mar;55(3):246-255. doi: 10.5414/CP202700. PMID: 28025965.
94. Hassankhan B., Yaghmaei P., Parivar K., Ebrahim-Habibi A. Effect of Beta-adrenergic blockade in High-fatinduced nonalcoholic fatty liver disease. Arch Pharma Pract. 2020;11(2):87-95.
95. Albillos A., Krag A. Beta-blockers in the era of precision medicine in patients with cirrhosis. J Hepatol. 2023;78(4):866-872. doi: 10.1016/j.jhep.2022.12.005.
96. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024. Erratum in: J Hepatol. 2018;69(5):1207. doi: 10.1016/j.jhep.2018.08.00.
97. Ivashkin V.T., Maevskaya M.V., Zharkova M.S. et al. Clinical Recommendations of the Russian Scientific Liver Society and Russian Gastroenterological Association on Diagnosis and Treatment of Liver Fibrosis, Cirrhosis and Their Complications.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(6):56-102. (In Russ.) doi: 10.22416/1382-4376-2021-31-6-56-102.@@ Ивашкин В.Т., Маевская М.В., Жаркова М.С. и др. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по диагностике и лечению фиброза и цирроза печени и их осложнений. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(6):56-102. doi: 10.22416/1382-4376-2021-31-6-56-102.
98. Statsenko M.E., Streltsova A.M. Metabolic effects of combination therapy with ramipril and indapamide in patients with arterial hypertension and non-alcoholic fatty liver disease. Arterial hypertension. 2021;27(4):472-481. (In Russ.) doi: 10.18705/1607-419X-2021-27-4-472-481.@@ Стаценко М.Е., Стрельцова А.М. Метаболические эффекты комбинированной терапии рамиприлом и индапамидом у пациентов с артериальной гипертензией и неалкогольной жировой болезнью печени. Артериальная гипертензия. 2021;27(4):472-481. doi: 10.18705/1607-419X-2021-27-4-472-481.
99. Statsenko M.E., Streltsova A.M., Turovets M.I. The impact of non-alcoholic fatty liver disease on arterial stiffness indices and the risk of cardiovascular complications in patients with arterial hypertension. Archives of Internal Medicine. 2020;10(4):296-304.(In Russ.) doi: 10.20514/2226-6704-2020-10-4-296-304.@@ Стаценко М.Е., Стрельцова А.М., Туровец М.И. Влияние неалкогольной жировой болезни печени на показатели артериальной жесткости и риск сердечно-сосудистых осложнений у пациентов с артериальной гипертензией. Архивъ внутренней медицины. 2020;10(4):296-304. doi: 10.20514/2226-6704-2020-10-4-296-304.
100. Efremova O.A., Chernobay P.E., Pogurelskaya E.P. Experience of using telmisartan, atorvastatin and ursodeoxycholic acid in patients with arterial hypertension in combination with non-alcoholic fatty liver disease. Siberian Scientific Medical Journal. 2021;41(5):75-82. (In Russ.) doi: 10.18699/SSMJ20210510.@@ Ефремова О.А., Чернобай П.Е., Погурельская Е.П. Опыт применения телмисартана, аторвастатина и урсодезоксихолевой кислоты у больных артериальной гипертонией в сочетании с неалкогольной жировой болезнью печени. Сибирский научный медицинский журнал. 2021;41(5):75-82. doi: 10.18699/SSMJ20210510.
Review
For citations:
Lazebnik L.B., Turkina S.V. Non-alcoholic fatty liver disease and hypertension: a bidirectional, mutually aggravating relationship. Experimental and Clinical Gastroenterology. 2024;(10):62-70. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-230-10-62-70
Views:
11
Email this article 